European expansion VISUfarma is a pan-European ophthalmic pharmaceutical company with a growing portfolio and distribution across 20+ countries, presenting a sales opportunity to expand presence in additional European markets and strengthen distributor channels.

acquisition activity Recent and rumored M&A activity involving VISUfarma (acquired by GHO Capital in 2016; potential acquisition by Lupin/Nanomi) signals consolidation in the ophthalmology space and may create partnership openings for technology licensing, contract manufacturing, or distribution agreements during integration.

new product launches Launches such as Xailin Ectoine and TREHAPAN Dry Eye drops indicate an active product development pipeline focused on dry eye and ocular surface protection, offering cross-sell opportunities for complementary devices, nutritional supplements, or adjacent therapy lines.

sustainability angle Partnership with Plastic Bank to convert plastic waste into currency demonstrates a commitment to sustainability, creating potential co-branding, repackaging, or eco-friendly packaging opportunities appealing to retailers and health systems with sustainability mandates.

customer reach With a multinational footprint, alliances with exclusive distributors, and a broad portfolio across dry eye, MGD, blepharitis, retinal health, and glaucoma, there are scalable sales opportunities through regional distributors, private-label arrangements, and targeted ophthalmology clinics and hospital channels.